Table 2: CISS score, NPC and PFV data recorded at the end of the 12th week of therapy.
–
|
–
|
Group I |
Group II |
CISS<16 |
Improvement ≥10 |
17 (32.7%) |
22 (44%) |
Improvement <10 |
9 (17.3%) |
13 (26%) |
CISS>16 |
Improvement ≥10 |
13 (25%) |
9 (18%) |
Improvement <10 |
13 (25%) |
6 (12%) |
Statistical Significance from Baseline |
X2=3.19, p<0.05 |
NPC<6 & Improvement ≥4 |
24 (46.2%) |
38 (76%) |
NPC<6 & Improvement <4 |
16 (30.7%) |
5 (10%) |
NPC>6 & Improvement ≥4 |
12 (23.1%) |
7 (14%) |
Statistical Significance from Baseline |
X2=3.257, p<0.05 |
Normal PFV & Improvement >10Δ |
22 (42.3%) |
32 (64%) |
Normal PFV & Improvement ≤10Δ |
16 (30.8%) |
14 (28%) |
Insufficient PFV & Improvement >10Δ |
14 (26.9%) |
4 (8%) |
Statistical Significance |
X2=5.195, p<0.05 |
Data are presented as mean ±SD & numbers; percentages are in parenthesis; CISS: Convergence insufficiency Symptom Survey score; NPC: Near convergence point; PFV: positive fusional vergence